ARTICLE | Emerging Company Profile
Apollo-created newco is using small molecules to activate the 20S proteasome, degrading proteins before they aggregate
By Danielle Golovin, Senior Biopharma Analyst
October 11, 2024 9:28 PM UTC
In an era where increasing numbers of companies are seeking to drag specific proteins to the proteasome for degradation, newly launched Booster sees value in revving up the proteasome broadly. The idea is to break down multiple misfolded proteins, not just one.
Booster Therapeutics GmbH launched Thursday with a $15 million seed round led by Apollo and Novo Holdings to develop small molecules that bind the 20S proteasome and accelerate its processing of any misfolded protein present, reducing the opportunity of the proteins to aggregate…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/653840/booster-activating-the-proteasome-to-degrade-misfolded-proteins